Using MMR/MSI markers to predict glioma vaccine effectiveness
The Role and Mechanism of MMR/MSI Phenotypes in Evaluating Vaccine Benefit in Glioblastoma
This study is testing if certain markers in brain tumor samples can help predict how well a new vaccine works for people with glioblastoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 360 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06043232 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on glioblastoma, a highly aggressive brain tumor, and aims to identify biomarkers that can predict the efficacy of tumor vaccines. It will collect tissue samples from glioma patients before and after receiving a dendritic cell vaccine, analyzing the role of mismatch repair (MMR) and microsatellite instability (MSI) in determining vaccine response. Additionally, advanced imaging techniques and deep learning will be employed to establish noninvasive markers for vaccine effectiveness. The ultimate goal is to enhance treatment strategies for glioblastoma patients by identifying those who are most likely to benefit from vaccination.
Who should consider this trial
Good fit: Ideal candidates for this study are glioma patients aged 18-80 who can provide tissue samples for analysis.
Not a fit: Patients currently participating in other clinical trials or pregnant women may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for glioblastoma patients.
How similar studies have performed: While tumor vaccines have shown promise in glioblastoma treatment, the specific use of MMR/MSI as predictive biomarkers is a novel approach that has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological results of frozen section during operation were gliomas (20 cases of who grade II, II and IV, respectively); 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.
Where this trial is running
Shanghai
- Huashan Hospital，Fudan University — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Di Chen, MD
- Email: dichen18@fudan.edu.cn
- Phone: 86-021-5288-9999
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.